Exact Therapeutics AS

Exact Therapeutics AS has a liquidity position characterized by a current ratio of 1.65, indicating that the company has sufficient current assets to cover its current liabilities. The company's cash and equivalents amount to NOK 24,346,550, which is a significant portion of its total assets of NOK 67,396,130. However, the company's operating cash flow is negative at NOK -66,989,560, and its free cash flow is also negative at NOK -88,603,340, suggesting that the company is not generating positive cash from its operations. In terms of profitability, Exact Therapeutics AS is currently unprofitable, with an operating income of NOK -84,877,320 and a net income of NOK -86,967,650. The company's return on equity is -2.83, and its return on assets is -1.29, both of which are negative and indicate poor performance relative to its equity and asset base. These metrics are below the industry median for biotechnology companies, which typically have higher returns due to successful product commercialization and strong R&D pipelines. The company's revenue is not disclosed in the provided data, and there is no information on geographic exposure or segment performance. However, the company's operations are likely concentrated in its core biotechnology and medical research activities, as it is a specialized firm in the healthcare diagnostics space. Exact Therapeutics AS is in a growth phase, but the data does not provide specific revenue growth figures. The company's capital expenditures are NOK -5,320,130, indicating some investment in infrastructure or equipment, but the overall financial position remains challenged by negative cash flows and losses. The company's future growth will depend on its ability to commercialize its therapies and generate positive cash flows from operations. The risk assessment for Exact Therapeutics AS indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.01, suggesting minimal leverage and a low risk of financial distress. However, the company's negative operating and free cash flows pose a potential risk to its long-term sustainability, and any future dilution would need to be carefully managed to avoid shareholder value erosion. Recent events for Exact Therapeutics AS include the latest financial reporting, which shows continued losses and negative cash flows. There are no specific recent filings or transcripts mentioned in the provided data that would indicate significant changes in the company's strategic direction or financial position.